early COVID-19 News
-
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for ...
-
Christof Industries Puts Innovation on Show
Styrian innovation was the focus of a meeting between Austrian Federal Chancellor Sebastian Kurz and representatives of successful Styrian industries on 2 June at the Graz Congress Centre. Products were presented that were developed in Styria in response to the Corona pandemic. The Chancellor thanked Christof CEO Johann Christof for the rapid and flexible deployment of sinTion units for ...
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Showcase
Empatica partnering with U.S. Army MRDC to deploy COVID-19 early detection wearable
BOSTON, Nov. 6, 2020 /PRNewswire/ -- Empatica has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to deploy a wearable and algorithm that enable the early and pre-symptomatic detection of COVID-19. The project's focus is on protecting the health of the general population by preventing outbreaks via early detection and alerting. Empatica's Aura algorithm gives a ...
-
Notitia Biotechnologies company announces expansion of study population for Covid-19 phase 2 study (COVGUT20) for NBT-NM108
After months of preparation, Notitia Biotechnologies Company (Notitia) announced that its COVID-19 Phase 2 study (COVGUT20) for NBT-NM108 has been given support by the Food and Drug Administration (FDA) to expand its study population to all symptomatic COVID-19 patients. "Previously, our trial focused on COVID-19 patients with type 2 diabetes and prediabetes. Now with this timely expansion to ...
-
Harnessing Wastewater Data to Support Healthcare Ecosystems
Early in the COVID-19 pandemic, wastewater-based epidemiology proved to be a vital tool for hospital systems and healthcare providers in safe operational planning. As wastewater data revealed the impending spike in COVID-19 cases due to the Omicron variant, for example, Boston Children’s Hospital responded by rescheduling nonemergency procedures to limit unnecessary exposure risk. ...
-
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in ...
-
OXITONE, the World`s First FDA-Cleared Wrist Sensor, Pulse Oximeter Monitoring Device to Detect the Early Symptoms of COVID-19 and Other Chronic Diseases
IRVINE, Calif., May 28, 2020 (Newswire.com) - betweenMD is very excited to announce our partnership with Oxitone, makers of the world's first FDA-cleared risk monitoring device. Oxitone developed a wearable monitoring device, specifically designed and FDA-cleared for in-home use for patients with respiratory failure. This unique solution is for prolonged monitoring for those at risk for ...
-
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Rutgers researcher invents Microbiota Formula to help high-risk patients fight Covid-19
A Rutgers scientist has invented an early treatment for COVID-19 to prevent severe complications and hospitalizations in patients with prediabetes and diabetes by increasing beneficial bacteria in the gut and reducing organisms that cause coronavirus. The treatment – created by researcher Liping Zhao – was given the Investigational New Drug status by the Food and Drug ...
-
Cytovale IntelliSep Test Demonstrates Potential to Rapidly Risk-Stratify Suspected COVID-19 Patients in New Study
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, today announced a new study on its investigational IntelliSep test has been published in the peer-reviewed journal PLOS ONE. The study, “Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the ...
-
What We Can Learn from the Spanish Flu
As the world reels from the recent impact of COVID-19, researchers are examining ways that the past can inform current and future pandemic response. The most widely documented historic pandemic is that of the Spanish flu in 1918, and while a different set of viruses means drastically different outcomes, comparing and contrasting past and present scenarios provides helpful insight into ...
-
Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV
Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the ...
-
How Do We Fill The Data Gap In Virtual Care?
Telehealth use skyrocketed in the early months of the Covid-19 pandemic when many health providers were forced to deliver services remotely. Although telehealth visits have dropped from their peak in 2020, they remain elevated even as many patients return to in-person care, according to the results of an analysis by Epic Research and the Kaiser Family Foundation. Survey results show that ...
-
Dogs Demonstrate Ability to Detect COVID-19
It is no secret that dogs have long been used for purposes other than companionship. Because of an acute sense of smell, dogs can be trained in medical arenas to detect cancer, diabetes, and other chronic diseases or conditions. You may have also seen the incredible sniffing power of dogs used in missing persons cases, illegal drugs, and hunting applications. Therefore, researchers are now ...
-
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19. Insilico's PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico's AI platform. The compound can be efficiently ...
-
Cority Announces New Solutions for Organizations to Manage the Healthy and Effective Recovery from COVID-19
Cority, the most trusted provider of environmental, health, safety, and quality (EHSQ) software today announced the immediate availability of its newly packaged COVID-19 Workplace Health and Continuity Solutions to help organizations effectively manage critical business processes during the graduated easing of restrictions and resumption of regular activities. The post-peak period is anticipated ...
By Cority
-
SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy
SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced that it has been granted approval by Health Canada to conduct a multiCentre Phase II prevention and efficacy trial for a front-line antiviral prevention and early treatment for use against COVID-19. SaNOtize also announced that new tests conducted by the Institute for Antiviral ...
-
Infection transmission prevention and control of Coronavirus (COVID-19) made possible through Genano Air Decontamination Units
Infection control procedures including work practices, protocols and controls, environmental hygiene, air filtration and appropriate use of Personal Protective Equipment (PPE) are all necessary to prevent infections from spreading during healthcare service delivery. But in the case of the recent Coronavirus (COVID-19) outbreak early detection and isolation of potentially infectious patients is ...
-
Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients
On August 1, 2021, the IT biotech company Molecular Health (MH) and Universitätsklinikum Essen kicked off a collaborative project funded by the BMG (Bundesministerium für Gesundheit [German Federal Ministry of Health]) to provide holistic and evidence-based care for COVID-19 patients. Using the MH Corona Explorer, a deeper understanding of the disease will be generated, linking the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you